---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-021559"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T09:20:33.827946+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Intellia Q3 net loss $113.2M; NTLA-2001 shows 93% TTR reduction, NTLA-2002 91% attack reduction

## Summary
- Net loss of $113.2M in Q3 2022 widened from $71.6M in Q3 2021; cash position $848.7M.
- Collaboration revenue rose to $13.3M from $7.2M; R&D expenses increased to $96.7M.
- NTLA-2001: mean serum TTR reductions of 93% (0.7 mg/kg) and 92% (1.0 mg/kg) at day 28.
- NTLA-2002: 25 mg dose led to 91% mean reduction in HAE attacks through 16-week observation.
- Expects to initiate NTLA-2002 Phase 2 in 1H 2023; plans IND filing for NTLA-3001 in 2023.

## SEC filing metadata
- accession: 0000950170-22-021559
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000095017022021559/0000950170-22-021559-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000095017022021559/ntla-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-021559
- JSON: https://secwatch.observer/filing/0000950170-22-021559.json
- Plain text: https://secwatch.observer/filing/0000950170-22-021559.txt

## Key facts
- Earnings Releases
  Intellia Therapeutics, Inc. reported financial results for third quarter ended September 30, 2022.
  - Period: third quarter ended September 30, 2022
  - Result: reported results
  source text: On November 3, 2022, Intellia Therapeutics, Inc. announced its financial results and business updates for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652130/000095017022021559/0000950170-22-021559-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.